Irbesartan and emodin on myocardial remodeling in goldblatt hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 375-380

  Chen, Can ^a   Liang, Zheng ^a   Chen, Qiang ^a   Li, Zhi Gen ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

angiotensin II; beta; 1; connective tissue growth factor; goldblatt hypertensive rats; myocardial remodeling; transforming growth factor

Indexed keywords

ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; EMODIN; IRBESARTAN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ECHOCARDIOGRAPHY; GENE EXPRESSION; GOLDBLATT HYPERTENSIVE RAT; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MYOCARDIAL REMODELING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

EID: 84867744180     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182650f1c.     Document Type: Article

References (31)

1. de Leeuw PW, Kroon AA. Hypertension and the development of heart failure. J Cardiovasc Pharmacol. 1998;32(suppl 1):S9-S15.
2. Onodera T, Okazaki F, Miyazaki H, et al. Perindopril reverses myocyte remodeling in the hypertensive heart. Hypertens Res. 2002;25:85-90.
3. Nishio M, Sakata Y, Mano T, et al. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens. 2007;25:455-461.
4. Suzuki H, Kusuyama T, Omori Y, et al. Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J. 2006;47:715-725.
5. Thai H, Guarraia D, Johnson N, et al. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation. J Cardiovasc Pharmacol. 2007;50:703-707.
6. Chen MM, Lam A, Abraham JA, et al. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 2000;32:1805-1819.
7. Dahly AJ, Hoagland KM, Flasch AK, et al. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2002;283:R757-R767.
8. Kasuga H, Ito Y, Sakamoto S, et al. Effects of anti-TGF-beta type II receptor antibody on experimental glomerulonephritis. Kidney Int. 2001; 60:1745-1755.
9. Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 2006;70:1234-1243.
10. Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Curr Opin Oncol. 2007;19:579-585.
11. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
12. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796.
13. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 1996;7:469-480.
14. Martin MM, Buckenberger JA, Jiang J, et al. TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2007;293:L790-L799.
15. Brezniceanu ML, Wei CC, Zhang SL, et al. Transforming growth factorbeta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int. 2006;69:1977-1985.
16. Zhang L, Chang CJ, Bacus SS, et al. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 1995;55:3890-3896.
17. Chang CH, Lin CC, Yang JJ, et al. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med. 1996;24:139-142.
18. Kuo YC, Meng HC, Tsai WJ. Regulation of cell proliferation, inflammatory cytokine production and calcium mobilization in primary human T lymphocytes by emodin from Polygonum hypoleucum Ohwi. Inflamm Res. 2001;50:73-82.
19. Zhan YT, Liu B, Li DG, et al. Mechanism of emodin for anti-fibrosis of liver. Zhonghua Gan Zang Bing Za Zhi. 2004;12:245-246 [in Chinese].
20. Wang CH, Gao ZQ, Ye B, et al. Effect of emodin on pancreatic fibrosis in rats. World J Gastroenterol. 2007;13(3):378-382.
21. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791.
22. Rosenkranz S, Flesch M, Amann K, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002;283:H1253-H1262.
23. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
24. Li RK, Li G, Mickle DA, et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 1997;96:874-881.
25. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci. 2006;63:2584-2596.
26. Iwanciw D, Rehm M, Porst M, et al. Induction of connective tissue growth factor by angiotensin II: integration of signaling pathways. Arterioscler Thromb Vasc Biol. 2003;23:1782-1787.
27. Tsutsui H, Matsushima S, Kinugawa S, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res. 2007;30:439-449.
28. Zhang RY, Wang LF, Zhang L, et al. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats. Chin Med J (Engl). 2006;119:649-655.
29. Kim SJ, Park K, Koeller D, et al. Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem. 1992;267: 13702-13707.
30. Arrick BA, Grendell RL, Griffin LA. Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol Cell Biol. 1994;14:619-628.
31. Wager RE, Assoian RK. A phorbol ester-regulated ribonuclease system controlling transforming growth factor beta 1 gene expression in hematopoietic cells. Mol Cell Biol. 1990;10:5983-5990.